OrbiMed Portfolio holdings
OrbiMed is an investment manager focused exclusively on healthcare, running public equity, private equity and private credit and royalty funds. The firm traces its origins to 1989, when Viren Mehta and Samuel Isaly, both pharmaceutical analysts at the bank S.G Warburg, set up the research and money-management firm Mehta & Isaly; in 1998 it split in two, with Isaly forming OrbiMed and Mehta forming Mehta Partners. Its public equity side covers long/short funds built around corporate events as well as closed-end investment trusts, and OrbiMed launched its first dedicated venture capital fund in 2000 and its first royalty and credit fund in 2011. Carl Gordon, Carter Neild and Geoffrey Hsu form the committee that leads the firm, which is owned and controlled by eight members.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$272M |
| 2 |
Gilead Sciences
GILD
|
+$251M |
| 3 |
Biogen
BIIB
|
+$219M |
| 4 |
Merck
MRK
|
+$193M |
| 5 |
Viatris
VTRS
|
+$149M |
Top Sells
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.07% |
| 2 | Miscellaneous | 15.74% |
| 3 | Financials | 2.05% |
| 4 | Technology | 0.14% |
| 5 | Utilities | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Amgen
AMGN
$252B
| $258M | 5.48% |
+2,619,400
| New | +$272M |
2013 Q2
0 quarters
|
|
|
2
Gilead Sciences
GILD
$212B
| $247M | 5.24% |
+4,821,800
| New | +$251M |
2013 Q2
0 quarters
|
|
|
3
Biogen
BIIB
$37.5B
| $221M | 4.68% |
+1,025,800
| New | +$219M |
2013 Q2
0 quarters
|
|
|
4
Merck
MRK
$369B
| $192M | 4.06% |
+4,323,419
| New | +$193M |
2013 Q2
0 quarters
|
|
|
5
Viatris
VTRS
$21.9B
| $155M | 3.28% |
+4,987,000
| New | +$149M |
2013 Q2
0 quarters
|
|
6
Thermo Fisher Scientific
TMO
$258B
| $151M | 3.2% |
+1,786,000
| New | +$149M |
2013 Q2
0 quarters
|
|
7
Bristol-Myers Squibb
BMY
$128B
| $148M | 3.15% |
+3,322,000
| New | +$144M |
2013 Q2
0 quarters
|
|
|
CELG
8
DELISTED
Celgene Corp
CELG
| $145M | 3.07% |
+2,472,800
| New | +$149M |
2013 Q2
0 quarters
|
|
9
Pfizer
PFE
$174B
| $137M | 2.91% |
+5,168,078
| New | +$143M |
2013 Q2
0 quarters
|
|
10
Illumina
ILMN
$35.6B
| $124M | 2.62% |
+1,698,050
| New | +$109M |
2013 Q2
0 quarters
|
|
11
Incyte
INCY
$24.4B
| $123M | 2.61% |
+5,606,000
| New | +$122M |
2013 Q2
0 quarters
|
|
12
HCA Healthcare
HCA
$102B
| $121M | 2.57% |
+3,366,300
| New | +$130M |
2013 Q2
0 quarters
|
|
|
ESRX
13
DELISTED
Express Scripts Holding Company
ESRX
| $118M | 2.5% |
+1,907,170
| New | +$115M |
2013 Q2
0 quarters
|
|
|
ONXX
14
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
| $102M | 2.16% |
+1,175,000
| New | +$108M |
2013 Q2
0 quarters
|
|
15
Elevance Health
ELV
$91.1B
| $97.1M | 2.06% |
+1,187,000
| New | +$88.8M |
2013 Q2
0 quarters
|
|
|
AET
16
DELISTED
Aetna Inc
AET
| $96.5M | 2.05% |
+1,519,000
| New | +$89.2M |
2013 Q2
0 quarters
|
|
|
ICPT
17
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $96.4M | 2.04% |
+2,150,634
| New | +$73.5M |
2013 Q2
0 quarters
|
|
18
Insulet
PODD
$10.4B
| $95.8M | 2.03% |
+3,048,500
| New | +$86.4M |
2013 Q2
0 quarters
|
|
|
19
CALL
Pfizer
PFE
$174B
| $90.7M | 1.92% |
+3,412,852
| New | +$94.3M |
2013 Q2
0 quarters
|
|
|
AGN
20
DELISTED
Allergan plc
AGN
| $82.4M | 1.75% |
+653,200
| New | +$74M |
2013 Q2
0 quarters
|
|
21
Agilent Technologies
A
$49.3B
| $79.3M | 1.68% |
+2,591,892
| New | +$80.5M |
2013 Q2
0 quarters
|
|
22
UnitedHealth
UNH
$365B
| $79.1M | 1.68% |
+1,208,000
| New | +$75.2M |
2013 Q2
0 quarters
|
|
23
Regeneron Pharmaceuticals
REGN
$95.5B
| $79M | 1.67% |
+351,100
| New | +$81.8M |
2013 Q2
0 quarters
|
|
24
BioMarin Pharmaceuticals
BMRN
$11.3B
| $74.8M | 1.58% |
+1,341,200
| New | +$83.6M |
2013 Q2
0 quarters
|
|
25
AbbVie
ABBV
$521B
| $73.5M | 1.56% |
+1,777,000
| New | +$77.7M |
2013 Q2
0 quarters
|
|
Similar funds
OrbiMed's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for OrbiMed, which disclosed 127 positions worth $4.72B. Its ten largest holdings account for 38% of the portfolio.
Its largest position is Amgen: 2,619,400 shares worth $258M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, followed by Miscellaneous and Financials.
- OrbiMed's largest Q2 2013 buy was Amgen: 2,619,400 shares worth $258M.
- OrbiMed's ten largest holdings make up 38% of its $4.72B portfolio in Q2 2013.
- OrbiMed disclosed 127 positions in Q2 2013, its first 13F filing on record.
Based on OrbiMed's 13F filing for Q2 2013, filed 14 Aug 2013.